Who are PVRV and pERIG Favirab®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rabies immune globulin (human), HyperRAB, Rabivax-S, Human rabies immunoglobulins, KamRAB - HRIG, HDCV Comparator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pvrv-and-perig-favirab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

PVRV and pERIG Favirab® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PVRV and pERIG Favirab® (PVRV and pERIG Favirab®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody immunoglobulin (rabies-specific). Area: Infectious Disease / Virology.

phase 3 Monoclonal antibody immunoglobulin (rabies-specific) Rabies virus glycoprotein Infectious Disease / Virology Biologic Live · refreshed every 30 min

Target snapshot

PVRV and pERIG Favirab® (PVRV and pERIG Favirab®) — Sanofi Pasteur, a Sanofi Company. PVRV and pERIG Favirab® are rabies immunoglobulins that provide passive post-exposure prophylaxis by neutralizing rabies virus through direct antibody binding.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PVRV and pERIG Favirab® TARGET	PVRV and pERIG Favirab®	Sanofi Pasteur, a Sanofi Company	phase 3	Monoclonal antibody immunoglobulin (rabies-specific)	Rabies virus glycoprotein
Rabies immune globulin (human)	Rabies immune globulin (human)	Sanofi Pasteur, a Sanofi Company	marketed	Passive immunizing agent; immunoglobulin	Rabies virus glycoprotein
HyperRAB	HyperRAB	Bio Products Laboratory	marketed	Rabies immunoglobulin (human)	Rabies virus glycoprotein
Rabivax-S	Rabivax-S	University of Oxford	marketed	Rabies vaccine	Rabies virus glycoprotein
Human rabies immunoglobulins	Human rabies immunoglobulins	Sanofi Pasteur, a Sanofi Company	phase 3	Immunoglobulin (passive immunization)	Rabies virus glycoprotein
KamRAB - HRIG	KamRAB - HRIG	Kamada, Ltd.	phase 3	Human rabies immunoglobulin (HRIG)	Rabies virus glycoprotein
HDCV Comparator	HDCV Comparator	Wilbur Chen, MD, MS	phase 3	Inactivated viral vaccine	Rabies virus glycoprotein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody immunoglobulin (rabies-specific) class)

Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PVRV and pERIG Favirab® — Competitive Intelligence Brief. https://druglandscape.com/ci/pvrv-and-perig-favirab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab